Posted inDermatology news Rheumatology
Dual IL‑17A/IL‑17F blockade with sonelokimab produces robust clinical responses in active psoriatic arthritis: phase 2 randomized trial
A phase 2 randomized, placebo‑controlled trial found sonelokimab — a nanobody that inhibits IL‑17A and IL‑17F — produced significant improvements in joint and skin outcomes in active psoriatic arthritis versus placebo, with an acceptable short‑term safety profile.